WA HB2072

Imposes a $0.01 per morphine milligram equivalent fee on prescription opioid manufacturers whose products exceed 100,000 morphine milligram equivalents dispensed in Washington per quarter, with the Department of Health issuing quarterly statements based on prescription monitoring program data

Creates the Prescription Opioid Impact Account to receive all collected fees, with expenditures limited to behavioral health outreach, treatment, and recovery support programs—50% must serve children, youth, and young adults

Caps administrative costs at 12% of annual deposits, excluding attorney general enforcement costs; requires reimbursement to the state general fund for 2025-2027 prescription monitoring program modification expenses

Establishes penalties of $100 per day or 10% of the fee due (whichever is greater) for manufacturers who fail to pay within 45 days, with the attorney general authorized to bring enforcement actions

Excludes buprenorphine, morphine, and methadone from the "prescription opioid" definition, and takes effect January 1, 2026